fda warning letters glp-1 compounders september 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading pharmaceutical ads The FDA has strictly clarified

References Centers for Medicare & Medicaid Services

Patel concurs and adds that every once in a while people who use his low-dosage (100 or 175 milligrams) topical treatment will experience a minor rash that quickly dissipates. These individuals should lower the dose to better suit their needs, he advises

If you go month-to-month, the risk is manageable

The compound is not scheduled under the Controlled Substances Act and is not explicitly banned but it also lacks FDA approval and has no place on the 503A Bulk Drug Substances List, which is the only pathway for licensed compounding pharmacies to legally dispense it

Can an IV Glutathione drip help in diabetes care

Individuals with a history of pancreatitis may need a different treatment plan